EA201700370A1 - PHARMACEUTICAL COMPOSITION WITH A MODIFIED DIFFICULT AND LONG-TERMLY SURVIVING, CONTAINING ASPARAGINATES - Google Patents
PHARMACEUTICAL COMPOSITION WITH A MODIFIED DIFFICULT AND LONG-TERMLY SURVIVING, CONTAINING ASPARAGINATESInfo
- Publication number
- EA201700370A1 EA201700370A1 EA201700370A EA201700370A EA201700370A1 EA 201700370 A1 EA201700370 A1 EA 201700370A1 EA 201700370 A EA201700370 A EA 201700370A EA 201700370 A EA201700370 A EA 201700370A EA 201700370 A1 EA201700370 A1 EA 201700370A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- shell
- pharmaceutical composition
- core
- composition
- release
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к фармацевтической промышленности и касается технологии изготовления лекарственного средства для регуляции метаболических процессов, связанных с дефицитом калия и магния в организме. Это лекарственное средство может быть использовано в терапии, например в кардиологии и спортивной медицине. Предложена фармацевтическая композиция с отсроченным и длительным высвобождением, содержащая смесь калиевой и магниевой солей аспарагиновой кислоты в виде рацематов, и/или их изомеров, и/или их смеси. Данная фармацевтическая композиция представляет собой твердую дозированную форму с направленным характером высвобождения действующего вещества, которая содержит ядро и оболочку - пленочное покрытие. Фармакокинетические преимущества заключаются в снижении побочного действия на слизистую оболочку желудка. Это свойство достигается путем нанесения оболочки специального состава, растворимой в щелочной среде кишечника, а также за счет оптимального разработанного соотношения действующих веществ и вспомогательных веществ как в ядре, так и в оболочке именно такого состава: наполнитель, разрыхляющее вещество и антифрикционное - в ядре; модификатор высвобождения, пластификатор, антифрикционный и красящий компонент - в оболочке твердой лекарственной формы.The invention relates to the pharmaceutical industry and relates to the technology of manufacturing medicines for the regulation of metabolic processes associated with deficiency of potassium and magnesium in the body. This drug can be used in therapy, for example in cardiology and sports medicine. The proposed pharmaceutical composition with a delayed and prolonged release, containing a mixture of potassium and magnesium salts of aspartic acid in the form of racemates, and / or their isomers, and / or mixtures thereof. This pharmaceutical composition is a solid dosage form with the directional nature of the release of the active substance, which contains the core and shell - film coating. Pharmacokinetic benefits are reduced side effects on the gastric mucosa. This property is achieved by applying a shell of a special composition, soluble in the alkaline environment of the intestine, and also due to the optimally developed ratio of active ingredients and auxiliary substances both in the core and in the shell of just such a composition: filler, disintegrant and antifriction substance - in the core; release modifier, plasticizer, antifriction and coloring component - in the shell of a solid dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201700370A1 true EA201700370A1 (en) | 2019-02-28 |
| EA033102B1 EA033102B1 (en) | 2019-08-30 |
Family
ID=65443153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA033102B1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04008665A (en) * | 2002-03-07 | 2004-12-06 | Novartis Ag | Pharmaceutical compositions. |
| RU2207853C1 (en) * | 2002-04-04 | 2003-07-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Pharmaceutical solid composition eliciting anti- arrhythmic activity and method for its preparing |
| RU2229879C1 (en) * | 2003-02-28 | 2004-06-10 | Закрытое акционерное общество "Биоамид" | Medicinal agent "asparkam-1" for regulation of metabolic processes and method for its preparing |
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| RU2336076C2 (en) * | 2006-06-22 | 2008-10-20 | Закрытое акционерное общество "Биоамид" | Peroral medical product for offset of magnesium deficiency in organism |
| RU2611339C2 (en) * | 2014-02-17 | 2017-02-21 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Pharmaceutical compositions with prolonged release for treating cerebrovascular disorders |
-
2017
- 2017-08-21 EA EA201700370A patent/EA033102B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA033102B1 (en) | 2019-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124052T1 (en) | ORALLY DISPERSIBLE TABLET CONTAINING ESTETROL | |
| JP2018527392A5 (en) | ||
| DK1931316T3 (en) | Controlled-release pharmaceutical compositions for acid-labile drugs | |
| BRPI0513598A (en) | enteric release coated tablet dosage forms | |
| HRP20200792T1 (en) | Pharmaceutical formulation comprising inositol | |
| BRPI0907414A2 (en) | oral dosage form containing at least two medicinal products | |
| RU2018140900A (en) | SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | |
| MX2019015733A (en) | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva. | |
| BR112015021630A2 (en) | stabilization of moisture sensitive drugs | |
| HRP20211761T1 (en) | Two-component composition comprising acetylsalicylic acid | |
| EA201700370A1 (en) | PHARMACEUTICAL COMPOSITION WITH A MODIFIED DIFFICULT AND LONG-TERMLY SURVIVING, CONTAINING ASPARAGINATES | |
| BRPI0700133A (en) | pharmaceutical composition comprising tramadol and ketoprofen in combination | |
| EA201691034A1 (en) | COMPOSITIONS IN SOLID SHORT-DOWN SHIPPING FOR ORAL ADMISSION | |
| EA201691693A3 (en) | COMBINED MEDICINE PREPARATION IN THE FORM OF SPELLING TABLETS AND METHOD OF ITS PREPARATION | |
| PE20171340A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | |
| BR112023002161A2 (en) | PALBOCICLIB SOLID DOSAGE FORMS | |
| EP2599482A1 (en) | Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate) | |
| RU2011134414A (en) | FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES | |
| WO2016204657A3 (en) | Method of producing a pharmaceutical composition of ademetionine and a dosage form thereof | |
| JP2017039687A (en) | Nalfurafine hydrochloride-containing capsule formulation | |
| MA43793B1 (en) | Process for the preparation of solid formulations of mesalazine | |
| EA202091611A2 (en) | FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID | |
| WO2016153222A3 (en) | Pharmaceutical composition comprising potassium salt of telmisartan, and preparation method therefor | |
| CO2023005753A2 (en) | Modified Release Soft Gelatin Capsules | |
| TWI645865B (en) | Hole-containing capsule shell for sublingual absorption and sublingual absorption capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG TJ TM |